Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>AptarGroup, Inc.'s third-quarter earnings call highlighted several key aspects of its performance and strategic direction.</li><li>The company reported adjusted earnings per share of $1.62 and a 6% increase in reported sales, with core sales growth of 1% year-over-year.</li><li>The Pharma segment exhibited strength, particularly in proprietary drug delivery systems for central nervous system applications, asthma, COPD, and ophthalmic treatments.</li></ul>

AptarGroup, Inc.'s third-quarter earnings call highlighted several key aspects of its performance and strategic direction.The company reported adjusted earnings per share of $1.62 and a 6% increase in reported sales, with core sales growth of 1% year-over-year.The Pharma segment exhibited strength, particularly in proprietary drug delivery systems for central nervous system applications, asthma, COPD, and ophthalmic treatments.

AptarGroup’s Latest Acquisition Is Turning Heads — The Sommaplast Synergy Explained!

<ul><li>AptarGroup, Inc. presented its third-quarter results, providing a balanced view of both achievements and challenges faced by the company.</li><li>The positive highlights include a commendable performance in the Pharma segment, which achieved significant growth driven by strong demand for drug delivery systems in areas like central nervous system therapeutics, asthma, and COPD, alongside a notable increase in injectables for GLP-1 medications.</li><li>Year-to-date, the Pharma segment experienced a consistent core sales growth, with injectables and active material science seeing delightful progress.</li></ul>

AptarGroup, Inc. presented its third-quarter results, providing a balanced view of both achievements and challenges faced by the company.The positive highlights include a commendable performance in the Pharma segment, which achieved significant growth driven by strong demand for drug delivery systems in areas like central nervous system therapeutics, asthma, and COPD, alongside a notable increase in injectables for GLP-1 medications.Year-to-date, the Pharma segment experienced a consistent core sales growth, with injectables and active material science seeing delightful progress.

AptarGroup Is Betting Big on Chronic Disease Treatments—Here’s Why It Could Pay Off!

<ul><li>AptarGroup, Inc. (referred to as Aptar) demonstrated a strong performance in its second quarter, with impressive financial outcomes and ongoing strategic initiatives.</li><li>The company's adjusted earnings per share (EPS) reached $1.66, representing an 18% increase compared to the prior year, exceeding the highest end of guidance.</li><li>Core sales witnessed growth, mainly fueled by the Pharma and Closures segments, highlighting robust demand for Aptar's drug delivery systems and dispensing closures.</li></ul>

AptarGroup, Inc. (referred to as Aptar) demonstrated a strong performance in its second quarter, with impressive financial outcomes and ongoing strategic initiatives.The company's adjusted earnings per share (EPS) reached $1.66, representing an 18% increase compared to the prior year, exceeding the highest end of guidance.Core sales witnessed growth, mainly fueled by the Pharma and Closures segments, highlighting robust demand for Aptar's drug delivery systems and dispensing closures.

AptarGroup: Resilience in Core Pharma Segment & Critical Growth Levers!

<ul><li>AptarGroup, Inc. delivered a mixed set of results for the first quarter of 2025, navigating a complex landscape with varying performance across its business segments.</li><li>Starting with the positives, Aptar's Pharma segment continues to be a strong contributor, with core sales increasing by 3%.</li><li>This growth was driven predominantly by the robust demand for proprietary drug delivery systems, including solutions for emergency medicines and chronic conditions such as asthma and COPD.</li></ul>

AptarGroup, Inc. delivered a mixed set of results for the first quarter of 2025, navigating a complex landscape with varying performance across its business segments.Starting with the positives, Aptar's Pharma segment continues to be a strong contributor, with core sales increasing by 3%.This growth was driven predominantly by the robust demand for proprietary drug delivery systems, including solutions for emergency medicines and chronic conditions such as asthma and COPD.

AptarGroup: Will Its Innovation in Dosing & Dispensing Technologies Pay Off?

Investment Advisor, Upslope Capital Management

Upslope Capital Management

Investment Advisor

Investment advisor for Upslope Partners Fund, LP, a global long/short equity hedge fund.

<ul><li>Q1 was challenging. However, in the two weeks since Mar 31, the world has changed, owing to an intense realignment of global trade policies.</li><li>This has swiftly aligned markets more with Upslope’s portfolio and approach.</li><li>April-to-date performance1 has been strong (approx. +7%), leaving the Fund +2% YTD (vs. -12% for the S&amp;P Midcap 400).</li></ul>

Q1 was challenging. However, in the two weeks since Mar 31, the world has changed, owing to an intense realignment of global trade policies.This has swiftly aligned markets more with Upslope’s portfolio and approach.April-to-date performance1 has been strong (approx. +7%), leaving the Fund +2% YTD (vs. -12% for the S&amp;P Midcap 400).

Upslope's Quarterly Investor Letter: 2025-Q1

United States

AptarGroup, Inc. designs, manufactures, and markets pumps, dispensing closures, and aerosol valves.  The Company's products are used for fragrance/cosmetics, personal care, pharmaceutical, household/industrial, and food products. AptarGroup operates worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Aptargroup Inc (ATR US)

AptarGroup’s Latest Acquisition Is Turning Heads — The Sommaplast Synergy Explained!

AptarGroup, Inc.'s third-quarter earnings call highlighted several key aspects of its performance and strategic direction. The company reported...

Baptista Research

AptarGroup Is Betting Big on Chronic Disease Treatments—Here’s Why It Could Pay Off!

AptarGroup, Inc. presented its third-quarter results, providing a balanced view of both achievements and challenges faced by the company. The...

Baptista Research

AptarGroup: Resilience in Core Pharma Segment & Critical Growth Levers!

AptarGroup, Inc. (referred to as Aptar) demonstrated a strong performance in its second quarter, with impressive financial outcomes and ongoing...

Baptista Research

AptarGroup: Will Its Innovation in Dosing & Dispensing Technologies Pay Off?

AptarGroup, Inc. delivered a mixed set of results for the first quarter of 2025, navigating a complex landscape with varying performance across...

Baptista Research

Upslope's Quarterly Investor Letter: 2025-Q1

Q1 was challenging. However, in the two weeks since Mar 31, the world has changed, owing to an intense realignment of global trade policies.

Upslope Capital Management

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)